Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Triptorelin
Drug ID BADD_D02297
Description Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
Indications and Usage Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Marketing Status approved; vet_approved
ATC Code L02AE04
DrugBank ID DB06825
KEGG ID D06247
MeSH ID D017329
PubChem ID 25074470
TTD Drug ID D03QRS
NDC Product Code 59149-006; 71161-106; 24338-150
UNII 9081Y98W2V
Synonyms Triptorelin Pamoate | Pamoate, Triptorelin | Triptorelin Embonate | Embonate, Triptorelin | CL-118532 | CL 118532 | CL118532 | Trelstar | Triptorelin | LHRH, Trp(6)- | GnRH, Trp(6)- | LHRH, Tryptophyl(6)- | D-Trp-6-LH-RH | 6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig) | Wy-42462 | Wy 42462 | Wy42462 | AY-25650 | AY 25650 | AY25650 | Decapeptyl | Decapeptyl Trimestral | Trimestral, Decapeptyl | Decapeptyl LP | Decapeptyl Depot
Chemical Information
Molecular Formula C64H82N18O13
CAS Registry Number 57773-63-4
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32) NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7 )NC(=O)C8CCC(=O)N8
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Bone cancer metastatic16.29.02.001; 15.09.03.004--Not Available
Cancer pain16.32.03.004--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Prostate cancer21.04.02.002; 16.25.01.001--Not Available
Breast disorder21.05.04.004--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Embolism24.01.01.009--
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation08.01.05.007; 10.02.01.089--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Pituitary tumour benign05.03.05.003; 16.37.02.001--Not Available
Red blood cell abnormality01.07.02.006--Not Available
Blood disorder01.05.01.004--Not Available
Metastasis16.22.01.001--Not Available
Hormone-dependent prostate cancer21.04.02.006; 16.25.01.003--Not Available
The 6th Page    First    Pre   6    Total 6 Pages